A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

IRB/UVA Tracking #
17721
Contact
Gracie Hockenberry
Contact Email
Contact Phone
1.434.297.7784
Phase
III
Primary purpose
Treatment
Cancer PI
Richard Hall
Status
OPEN TO ACCRUAL
Ages
Adult